Deciduous Therapeutics has emerged from stealth with $6.5 million in early funding to develop therapies that leverage the natural immune system to clear senescent cells.
The registration of the 'STOP-Sepsis' trial marks an expansion of senolytic therapeutic evaluation into acute systemic inflammatory conditions, shifting the clinical focus of cellular senescence away from purely chronic age-related diseases.
